BlackRock
INTS icon

BlackRock’s Intensity Therapeutics INTS Stock Holding History

BlackRock’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-873
Closed -$43K – 5525
2025
Q1 		$43K Sell
873
-17
-2% -$945 ﹤0.01% 4947
2024
Q4 		$39.2K Buy
890
+5
+0.6% +$363 ﹤0.01% 4997
2024
Q3 		$84.5K Buy
885
+329
+59% +$36.5K ﹤0.01% 4706
2024
Q2 		$68.1K Buy
556
+127
+30% +$14.4K ﹤0.01% 4791
2024
Q1 		$55.8K Sell
429
-11
-3% -$1.32K ﹤0.01% 4847
2023
Q4 		$94.2K Buy
440
+30
+7% +$3.16K ﹤0.01% 4820
2023
Q3 		$40.6K Buy
+410
New +$56.6K ﹤0.01% 5037

Other funds holding INTS

SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

BlackRock's INTS Position: Q2 2025 in Review

BlackRock sold out of Intensity Therapeutics (INTS) in Q2 2025, closing a stake of 873 shares — an estimated $43K sold.

BlackRock first reported a position in INTS in Q3 2023 and held it in 7 quarters. The position peaked at $94.2K in Q4 2023. 27 funds tracked by Wall St. Rank hold INTS as of Q2 2025.

  • BlackRock reported no remaining Intensity Therapeutics position as of Q2 2025 after selling out during the quarter.
  • BlackRock sold 873 Intensity Therapeutics shares in Q2 2025, an estimated $43K.
  • BlackRock first reported a position in Intensity Therapeutics in Q3 2023 and held it in 7 quarters.
  • BlackRock's Intensity Therapeutics position peaked at $94.2K in Q4 2023.
  • 27 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2025.

Based on BlackRock's 13F filing for Q2 2025, filed 12 Aug 2025.